Skip to main content
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc — Investor Relations & Filings

Ticker · PTGX ISIN · US74366E1029 US Manufacturing
Open in API
Filings indexed 641 across all filing types
Latest filing 2019-05-08 Earnings Release
Country US United States of America
Listing US PTGX

About Protagonist Therapeutics, Inc

https://www.protagonist-inc.com/

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of peptide-based new chemical entities. The company utilizes its proprietary technology platform to engineer novel oral and injectable peptide therapeutics. Its development pipeline is focused on creating treatments for rare and prevalent diseases, particularly in the areas of hematology and gastroenterology, addressing significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 8, 2019, reporting the financial results for the quarter ended March 31, 2019. It includes a press release titled 'Protagonist Therapeutics Reports First Quarter 2019 Financial Results.' The content is a current report disclosing quarterly financial results, which aligns with an Earnings Release (ER) filing. The document length is 4241 characters, which is typical for an 8-K earnings release. There is no indication that this is a full interim report with detailed financial statements, so it is not classified as an Interim/Quarterly Report (IR). It is not a report publication announcement or a certification, so it is not RPA or RNS. Therefore, the best classification is Earnings Release (ER).
2019-05-08 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 7, 2019, by Protagonist Therapeutics, Inc. It reports the entry into a material definitive agreement, specifically an amendment to a License and Collaboration Agreement with Janssen Biotech, Inc. The content focuses on the terms of the amendment, milestone payments, and collaboration details. There are no financial statements or quarterly/yearly financial results presented. The document is a current report disclosing a material contract event, which aligns with the purpose of Form 8-K filings. This type of filing is best classified under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Earnings Release, or Capital Update.
2019-05-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement related to the solicitation of shareholder votes for the Annual Meeting. It includes details about voting items such as election of directors and ratification of auditors, and instructions on how to access proxy materials. It is not the Annual Report (10-K) itself, but proxy materials related to shareholder voting. The document is not a report publication announcement since it contains substantive proxy solicitation content. Therefore, the filing type corresponds to Proxy Solicitation & Information Statement (PSI).
2019-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2019-04-26 English
FORM 4 SUBMISSION
Director's Dealing
2019-04-03 English
FORM 4 SUBMISSION
Director's Dealing
2019-04-03 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.